These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 34049688)

  • 1. Efficacy of COVID-19 vaccines: From clinical trials to real life.
    Deplanque D; Launay O
    Therapie; 2021; 76(4):277-283. PubMed ID: 34049688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.
    Zhang Y; Banga Ndzouboukou JL; Gan M; Lin X; Fan X
    Front Immunol; 2021; 12():771242. PubMed ID: 34880867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal COVID-19 vaccines: From bench to bed.
    Alu A; Chen L; Lei H; Wei Y; Tian X; Wei X
    EBioMedicine; 2022 Feb; 76():103841. PubMed ID: 35085851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.
    Sharif N; Alzahrani KJ; Ahmed SN; Dey SK
    Front Immunol; 2021; 12():714170. PubMed ID: 34707602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective.
    Funk CD; Laferrière C; Ardakani A
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The conundrum of current anti-SARS-CoV-2 vaccines.
    Federico M
    Cytokine Growth Factor Rev; 2021 Aug; 60():46-51. PubMed ID: 33714693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
    Hodgson SH; Mansatta K; Mallett G; Harris V; Emary KRW; Pollard AJ
    Lancet Infect Dis; 2021 Feb; 21(2):e26-e35. PubMed ID: 33125914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19.
    Chang A; Yu J
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.
    Abdullahi IN; Emeribe AU; Adekola HA; Abubakar SD; Dangana A; Shuwa HA; Nwoba ST; Mustapha JO; Haruna MT; Olowookere KA; Animasaun OS; Ugwu CE; Onoja SO; Gadama AS; Mohammed M; Daneji IM; Amadu DO; Ghamba PE; Onukegbe NB; Shehu MS; Isomah C; Babayo A; Ahmad AE
    Hum Vaccin Immunother; 2021 Mar; 17(3):620-637. PubMed ID: 32936732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
    Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z;
    Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the road to ending the COVID-19 pandemic: Are we there yet?
    Case JB; Winkler ES; Errico JM; Diamond MS
    Virology; 2021 May; 557():70-85. PubMed ID: 33676349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principles and Challenges in anti-COVID-19 Vaccine Development.
    Strizova Z; Smetanova J; Bartunkova J; Milota T
    Int Arch Allergy Immunol; 2021; 182(4):339-349. PubMed ID: 33524979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 vaccines: a triumph of science and collaboration.
    Golob JL; Lugogo N; Lauring AS; Lok AS
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33822773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
    Sharma O; Sultan AA; Ding H; Triggle CR
    Front Immunol; 2020; 11():585354. PubMed ID: 33163000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants.
    Rotondo JC; Martini F; Maritati M; Mazziotta C; Di Mauro G; Lanzillotti C; Barp N; Gallerani A; Tognon M; Contini C
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.